July 10, 2025
| This week’s gene therapy news and insights for biopharma leaders
The cell therapy developer, which raised nearly $500 million in 2023 on the promise of its CAR-T work, has floundered since a safety setback forced it to scrap its lead candidate.
|
The agency disclosed a tranche of more than 200 complete response letters from the past five years, but only those involving medicines that it later cleared.
|
UPDATED
Some two dozen biotech developers of PROTACs, molecular glues and other types of protein-degrading drugs have sprung up over the past two decades.
|
FDA staff cuts and significant turnover at the office regulating cell therapies have heightened pressure on developers, many of whom have already shifted strategies. Explore what the future holds for the market in
|
From Our Library
Trendline
Supported by Marken
|
View all resources
What We're Reading
Time
|
BioSpace
|
Endpoints
|
Dive Into a Topic
|